Debt-to-equity of ARS Pharmaceuticals, Inc. from 30 Sep 2021 to 31 Dec 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: ARS Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 31 Dec 2025.
ARS Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 96%, a 611% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

ARS Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q4 2025	96%	+83%	+611%	31 Dec 2025
Q3 2025	65%	+62%	+1827%	30 Sep 2025
Q2 2025	38%	+35%	+1313%	30 Jun 2025
Q1 2025	24%	+21%	+716%	31 Mar 2025
Q4 2024	14%	+10%	+290%	31 Dec 2024
Q3 2024	3.4%	-0.54%	-14%	30 Sep 2024
Q2 2024	2.7%	-1.8%	-41%	30 Jun 2024
Q1 2024	2.9%	-5.6%	-66%	31 Mar 2024
Q4 2023	3.5%	-30%	-90%	31 Dec 2023
Q3 2023	3.9%	+38%		30 Sep 2023
Q2 2023	4.5%	-28%	-86%	30 Jun 2023
Q1 2023	8.6%	-3.4%	-29%	31 Mar 2023
Q4 2022	33%	+27%	+401%	31 Dec 2022
Q3 2022	-34%	-40%	-651%	30 Sep 2022
Q2 2022	33%			30 Jun 2022
Q1 2022	12%			31 Mar 2022
Q4 2021	6.7%			31 Dec 2021
Q3 2021	6.1%			30 Sep 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.